Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement

Bexarotene (BEX) was approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL). The poor aqueous solubility causes the low bioavailability of the drug and thereby limits the clinical application. In this study, we developed a GCN-based deep learning model (CocrystalGCN) for i...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Fu Xiao, Yinxiang Cheng, Jian-Rong Wang, Dingyan Wang, Yuanyuan Zhang, Kaixian Chen, Xuefeng Mei, Xiaomin Luo
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2022-10-01
Schriftenreihe:	Pharmaceutics
Schlagworte:	bexarotene cocrystal prediction GCN bioavailability
Online-Zugang:	https://www.mdpi.com/1999-4923/14/10/2198
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!